Latest filing published 16 Jun 2025 for Sangamo Therapeutics, INC. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Filings by Karen L. Smith span 6 companies, the busiest being Sangamo Therapeutics, Inc, Antares Pharma, Inc. and Aurinia Pharmaceuticals Inc. We count 12 filings; the first trade dates from 7 May 2021 and the latest from 12 June 2025.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
The newest entry dates from 16 June 2025: a share grant, in Sangamo Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
12 of 12 declarations